A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether cetuximab (Erbitux®) with cisplatin and
capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective.